UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

Health science reports, 2020-06, Vol.3 (2), p.e145-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

The Journal of infectious diseases, 2019-01, Vol.219 (2), p.177-185

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults

Antiviral therapy, 2018-01, Vol.23 (7), p.555-566

2018

Link zum Volltext

Verfügbarkeit prüfen

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Virology journal, 2017-05, Vol.14 (1), p.101-101, Article 101

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model

Antimicrobial Agents and Chemotherapy, 2010-11, Vol.54 (11), p.4534-4539

2010

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients

Journal of hepatology, 2022-07, Vol.77, p.S72-S73

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

European journal of pharmaceutics and biopharmaceutics, 2009-08, Vol.72 (3), p.502-508

2009

Link zum Volltext

Verfügbarkeit prüfen

FRI-180-JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers

Journal of hepatology, 2019-04, Vol.70 (1), p.e469-e469

2019

Link zum Volltext

Verfügbarkeit prüfen

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults

Antiviral therapy, 2023-06, Vol.28 (3), p.13596535231172878-13596535231172878

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

Journal of antimicrobial chemotherapy, 2022-03, Vol.77 (4), p.1102-1110

2022

Link zum Volltext

Verfügbarkeit prüfen

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

Gastroenterology (New York, N.Y. 1943), 2010-03, Vol.138 (3), p.913-921

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults

Antiviral therapy, 2021-05, Vol.26 (3-5), p.58-68

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants

Antiviral therapy, 2023-02, Vol.28 (1), p.13596535231151626

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

Antiviral therapy, 2021-01, Vol.26 (1-2), p.13-24

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen

Antimicrobial agents and chemotherapy, 2017-12, Vol.61 (12)

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the interaction of 2‐hydroxypropyl‐β‐cyclodextrin with itraconazole at pH 2, 4, and 7

Journal of pharmaceutical sciences, 2002-06, Vol.91 (6), p.1414-1422

2002

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase

Journal of medicinal chemistry, 2014-03, Vol.57 (5), p.1880-1892

2014

Link zum Volltext

Verfügbarkeit prüfen

Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)

Journal of medicinal chemistry, 2008-02, Vol.51 (4), p.875-896

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

BMC gastroenterology, 2017-02, Vol.17 (1), p.26-26, Article 26

2017

Link zum Volltext

Verfügbarkeit prüfen

Powder for reconstitution of the anti-HIV-1 drug TMC278 – Formulation development, stability and animal studies

European journal of pharmaceutics and biopharmaceutics, 2008-11, Vol.70 (3), p.853-860

2008

Link zum Volltext

Verfügbarkeit prüfen

Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs

European journal of pharmaceutical sciences, 2010-10, Vol.41 (2), p.193-200

2010

Link zum Volltext

Verfügbarkeit prüfen

Dog model with implanted pump to test boosters for antiretroviral medication

International journal of pharmaceutics, 2008-05, Vol.355 (1), p.45-52

2008

Link zum Volltext

Verfügbarkeit prüfen

5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

Bioorganic & medicinal chemistry letters, 2003-05, Vol.13 (9), p.1543-1547

2003

Link zum Volltext

Verfügbarkeit prüfen

Substituted azoloquinolines and -quinazolines as new potent Farnesyl Protein Transferase inhibitors

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4365-4369

2003

Link zum Volltext

Verfügbarkeit prüfen

About the Kinetics of Partial Wetting

Journal of colloid and interface science, 1993-10, Vol.160 (2), p.387-396

1993

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(22)
Pharmacology & Pharmacy
(17)
Humans
(10)
Animals
(9)
Biological And Medical Sciences
(9)
Infectious Diseases
(9)
Medical Sciences
(9)
Pharmacology. Drug Treatments
(9)
Male
(8)
Pharmacokinetics
(8)
Adult
(7)
Chemistry
(6)
Virology
(6)
Antiviral Agents - Pharmacokinetics
(5)
Chemistry, Medicinal
(5)
Female
(5)
General Pharmacology
(5)
Pharmaceutical Technology. Pharmaceutical Industry
(5)
Physical Sciences
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model

Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

FRI-180-JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen

Characterization of the interaction of 2‐hydroxypropyl‐β‐cyclodextrin with itraconazole at pH 2, 4, and 7

Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase

Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Powder for reconstitution of the anti-HIV-1 drug TMC278 – Formulation development, stability and animal studies

Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs

Dog model with implanted pump to test boosters for antiretroviral medication

5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

Substituted azoloquinolines and -quinazolines as new potent Farnesyl Protein Transferase inhibitors

About the Kinetics of Partial Wetting

Suchergebnisse filtern